(E)-3-carboxymethylidene-4-hydroxy-1-triphenylmethylpiperidine 、 盐酸 在
甲苯 作用下,
以
正丁醇 为溶剂,
反应 1.0h,
以whereby 3.43 g (yield: 100%) of (E)-3-butoxycarbonylmethylidene-4-hydroxypiperidine hydrochloride were obtained as a white solid的产率得到(E)-3-butoxycarbonylmethylidene-4-hydroxypiperidine hydrochloride
Cyclic amino compounds represented by general formula (I) or pharmacologically acceptable salts thereof having an excellent antiplatelet aggregation effect; etc. and thus being useful as preventives or remedies for embolism, thrombosis or arterial sclerosis wherein R1 represents optionally substituted phenyl; R2 represents optionally substituted aliphatic acyl, optionally substituted benzoyl or alkoxycarbonyl; and R3 represents substituted and optionally ring-fused saturated cyclic amino.
A cyclic amino compound represented by the following formula:
or a pharmacologically acceptable salt thereof. R1 is a substitutable phenyl group. R2 is a substitutable aliphatic acyl group, a substitutable benzoyl group or an alkoxycarbonyl group. R3 is a substituted, saturated cyclic amino group which may optionally have a fused ring. These compounds and salts have excellent platelet aggregation inhibitory action. They are useful for the prevention and/or treatment of embolism, thrombosis or arteriosclerosis and other conditions resulting from platelet aggregation.